CurrentBlue Cross Blue Shield - OklahomaPolicy N/A

Enhanced Dispensing Limits (DL)

Defines quantity/dispensing limits for specific prescription drugs and formulations for members of Blue Cross and Blue Shield plan divisions listed; informs patients/providers of coverage limits and member cost responsibility for quantities beyond limits.

Policy Summary

PayerBlue Cross Blue Shield - Oklahoma

PolicyEnhanced Dispensing Limits (DL)

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateN/A

Key ActionVerify plan-specific dispensing limits or exclusions with the member's plan or by calling the number on the back of the member ID card.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

30/28/180common dispensing timeframes used in limits

2common biologic pens/syringes per 28 days

30most common tablet limit per 30 days

~20+distinct drug entries in excerpt

Coverage Criteria and General Rules

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

General rules: Coverage is limited to specified dispensing quantities per drug and formulation as listed in the policy (e.g., per 28, 30, 90, 180, or 365 day windows).see individual drug entries

Limits may vary by state or plan; some limits apply cumulatively across formulations or strengths (see product lines).

Member cost responsibility for over-limit quantities: If a prescriber orders a greater quantity than the dispensing limit, the member may still obtain the medication but will be responsible for the full cost of the quantity beyond the coverage allowance.

Members and providers should verify plan-specific applications of limits by reviewing plan materials or calling the number on the back of the member ID card.

Applicability: Dispensing limits shown in the list may not apply to all members and may vary based on state regulations; some drugs or categories may have plan-specific exclusions or mail-order restrictions.

See plan materials for member-specific coverage.

Quantity limits

Covered when dispensed within the stated quantity/dispensing limits

Standard insulin/disposable limits: Most injectable insulins and pen formulations: Dispensing Limit = 100 mLs Per 30 DAYS.100 mLs Per 30 DAYS

Quantity limits are cumulative across injectable formulations and apply to listed brands/generics (e.g., glargine, lispro, glulisine, concentrated products).

Pod/reservoir limits: Insulin infusion disposable pump reservoirs (Omnipod and similar): Dispensing Limit = 30 Pods Per 30 DAYS.30 Pods Per 30 DAYS

Includes multiple pod generations (Gen 3–5) and branded kits.

Pen needles and syringes: Insulin pen needles and insulin syringes: Dispensing Limit = 300 units (needles or syringes) Per 30 DAYS; quantity limits are cumulative across like items.300 Per 30 DAYS

Applies across listed SKUs and sizes (e.g., 29g, 30g, 31g variants).

Pump starter/intro kits: Insulin infusion starter/intro kits and insulin pump devices: Dispensing Limit = 1 Kit Per 720 DAYS.1 Per 720 DAYS

Applies to listed starter kits and pump devices (e.g., Omnipod Dash/5, Ilet).

Inhaled and concentrated insulin: Inhaled insulin cartridges and concentrated U-500 insulin: Dispensing limits as listed per product (cartridge counts vary by strength; Humulin R U-500 = 100 mLs Per 30 DAYS).

Refer to product-specific lines for exact cartridge counts or mL limits.

Some plan-level exclusions may apply. The policy notes that some plans may exclude coverage for certain agents or drug categories (for example, erectile dysfunction agents such as Viagra) and that dispensing limits may not apply to all members or may vary by state regulation. Members and providers should verify whether specific exclusions apply by reviewing plan materials or calling the number on the back of the member ID card.

For the GLP-1 receptor agonist class the policy enforces a fill limit of one injectable GLP-1 agent and one strength per 28 days. This rule is shown across listed GLP‑1 entries (for example, exenatide and exenatide extended‑release formulations) and precludes dispensing multiple injectable GLP‑1 agents or multiple strengths within a single 28‑day period.

The document provides numerous dispensing limits expressed per product and strength (e.g., insulin combination Soliqua 100/33 — 6 pens per 30 days; many injectable insulins — 100 mLs per 30 days; and insulin pump kits — 1 kit per 720 days). Entries also include brand/generic designations (codes such as B, G, BG) alongside the dispensing limits. This excerpt does not specify additional prior authorization rules within these lines; prior authorization implications are addressed elsewhere in the policy.

Per-Product Quantity Limits (Selected Entries)

abacavir sulfate solution 20 mg/mL (Ziagen)

Productabacavir sulfate solution 20 mg/mL (Ziagen)

Dispensing limit960 mLs Per 30 DAYS

Formulary flagBG (Generic and Brand)

abacavir sulfate tablet 300 mg (Ziagen)

Productabacavir sulfate tablets 300 mg (Ziagen)

Dispensing limit60 Tablets Per 30 DAYS

Formulary flagBG (Generic and Brand)

abaloparatide pen‑injector (Tymlos)

Productabaloparatide subcutaneous solution pen‑injector 3120 mcg/1.56 mL (Tymlos)

Dispensing limit1.56 mLs Per 30 DAYS (equals 1 injection)

Formulary flagB (Brand Only)

abatacept for IV solution (Orencia)

Productabatacept for IV solution 250 mg (Orencia)

Dispensing limit4 Vials Per 28 DAYS

Formulary flagB (Brand Only)

abemaciclib tablets (Verzenio)

Productabemaciclib tablets (Verzenio) — various strengths

Dispensing limit60 Tablets Per 30 DAYS

Formulary flagB (Brand Only)

acyclovir buccal tablet (Sitavig)

Productacyclovir buccal tablet 50 mg (Sitavig)

Dispensing limit2 Tablets Per 180 DAYS

Formulary flagB (Brand Only)

adalimumab auto‑injector kits / pens / syringes

Productadalimumab auto‑injector kits / pens / syringes (Humira and variants)

Dispensing limitExamples include 1 Kit Per 180 DAYS; 2 Pens or 2 Syringes Per 28 DAYS

Formulary flagB (Brand Only) for many listed adalimumab variants

adalimumab (biosimilars and brands)

Product groupadalimumab biosimilars and brand variants

Common dispensing limit2 Pens or Syringes Per 28 DAYS for many biosimilars/brands

Formulary flagOften designated B (Brand Only) in listings

afatinib (Gilotrif)

Productafatinib (Gilotrif) tablets

Dispensing limit30 Tablets Per 30 DAYS

Formulary flagB (Brand Only)

amifampridine (Firdapse)

Productamifampridine (Firdapse)

Dispensing limit300 Tablets Per 30 DAYS

Formulary flagB (Brand Only)

albuterol solution for nebulization

Productalbuterol solution for nebulization (various strengths)

Dispensing limitsExamples: 120 Vials Per 30 DAYS; 60 mLs Per 30 DAYS; 125 Vials Per 30 DAYS depending on strength

Formulary flagBG or G depending on strength/product

amikacin liposome inhalation (Arikayce)

Productamikacin liposome inhalation (Arikayce)

Dispensing limit28 Vials Per 28 DAYS

Formulary flagB (Brand Only)

amphetamines — sample listings

Productamphetamine ER formulations (examples: Dyanavel XR, Adzenys XR‑ODT)

Dispensing limitsCommon examples: 30 or 60 Tablets Per 30 DAYS depending on strength/formulation

Formulary flagDesignations vary (B or BG) per listing

Mydayis / Adderall examples

ProductMydayis / Adderall (various strengths)

Dispensing limitsMydayis — 30 Capsules Per 30 DAYS; Adderall — commonly 60–90 Tablets Per 30 DAYS depending on strength

Formulary flagBG for many listed stimulant entries

Actionable Notes for Providers and Pharmacies

Note

Dispensing limits notice — biologics and specialty injectables

Dispensing limits for biologics: Many biologic and specialty injectable products are subject to specific per‑period dispensing limits (for example, commonly 1–4 pens or syringes per 28 days). Verify the listed Dispensing Limit for the specific biologic prior to dispensing; cumulative limits across strengths or formulations may apply.

Examples: adalimumab biosimilars — 2 pens/syringes per 28 days; dupilumab — 2 syringes per 28 days (100 mg) or 4 syringes per 28 days (300 mg); ixekizumab — 1 syringe per 28 days; evolocumab — up to 6 pens per 28 days.

Prior Authorization

Prior authorization likely when requesting quantities above listed limits

Prior authorization likely for over‑limit dispensing: Requests for quantities that exceed published dispensing limits are at risk for denial and typically require prior authorization (PA). High‑cost biologics, specialty agents, or items designated Brand Only frequently trigger PA when requested above the listed limit.

If prescriber documents medical necessity for quantities above the limit, submit supporting clinical justification with the PA request.
Brand‑only specialty injectables often require PA or specialty pharmacy handling for any non‑standard quantity.

Prior Authorization

PA may be required — check full policy/process

Prior authorization (not specified in the excerpt): The source listing includes many products with dispensing limits but does not always state the specific PA criteria or process. Use the payer’s full policy and PA portal/process to determine exact PA requirements and required documentation.

When PA is not explicitly listed here, assume the payer’s standard PA rules for specialty/high‑cost drugs apply and follow the payer’s online submission instructions.

Prior Authorization

Quantity limits that typically trigger PA or review

Quantity limits imply prior authorization in many cases: Low‑frequency or low‑quantity limits (for example, 1 kit per 180 or 720 days, 4–6 pens per 28 days, or single‑item per period limits) commonly indicate prior authorization or clinical review is required for replacement or higher quantities.

Examples: pump/kit limits (1 kit per 720 days), starter packs (1 pack per 180 days), and some monoclonal antibodies with 1 syringe/pen per 28 days.
For replacement requests outside the stated interval, include documentation supporting clinical need and timing.

Billing Rule

Formulary preference and claim adherence

Formulary preference and limits: Entries marked Brand‑Only (B) or Brand/Generic designations indicate formulary preference and may affect coverage and PA requirements. Dispensing must match the plan’s brand/generic designation when adjudicating claims.

Pharmacies should submit claims consistent with the listed B/BG/G status; dispensing a brand product when the plan prefers generic may lead to denial or requirement for PA.
Members/providers should verify whether a therapeutic alternative or step therapy requirement applies via plan materials or member services.

Billing Rule

GLP‑1 injectable fill limit — one agent/one strength per 28 days

Fill limit for injectable GLP‑1 agents: For GLP‑1 injectables the policy enforces a class fill limit — only one GLP‑1 agent and one strength may be filled per 28 days. Refill windows and the 28‑day agent/strength restriction apply.

Examples: dulaglutide (Trulicity) and exenatide extended‑release (Bydureon) show 4 pens per 28 days and the one‑agent/one‑strength per 28 days fill limit.
Pharmacies must ensure claims reflect a single GLP‑1 agent/strength per 28‑day period to avoid denial.

Prior Authorization

PA may apply — specialty and limited‑distribution products

Prior authorization may apply for high‑cost or limited‑distribution specialty items: Many specialty products with small dispensing limits or Brand‑Only status will require PA per payer rules; check the specialty pharmacy or PA routing for these agents.

Examples include limited‑distribution monoclonal antibodies and specialty fertility or factor products.
Use payer’s specialty channel and include clinical dosing calculations when applicable.

Prior Authorization

PA details — consult the complete policy and PA instructions

Prior authorization (see full policy): For specific PA criteria, required clinical documentation, and the payer’s submission process, consult the complete policy and PA forms. The excerpted dispensing limits do not replace the full PA requirements.

Include dosing rationale, prior treatments, laboratory or weight‑based calculations (when relevant), and expected frequency when submitting a PA.
For drugs with vial/IU calculations (e.g., factor products, C1 esterase inhibitors), provide calculation details to support requested quantities.

Prior Authorization

Specialty limits frequently imply PA and specialty pharmacy handling

Prior authorization implied by specialty limits: Low frequency limits (for example, 1 syringe per 28 days or limited pens per month) and complex packaging/kit rules often indicate specialty pharmacy management and PA. Plan administrators may require documentation or prior approval for exceptions.

Examples: ixekizumab (Taltz) 1 syringe per 28 days; dupilumab carton/syringe packaging rules.
Coordinate with the payer’s specialty pharmacy vendor for authorizations and fulfillment.

Prior Authorization

PA needed for quantities beyond listed limits

Prior authorization for items exceeding quantity limits: When a prescriber requests replacement earlier than permitted or a higher quantity than the Dispensing Limit, submit a PA with supporting clinical justification. Requests lacking documentation are at risk for denial.

Document reason for early replacement (e.g., loss, breakage, clinical need) and include relevant clinical notes and prior dosing history.
Member may be responsible for cost of excess quantity if PA is not obtained or request denied.

Prior Authorization

PA may be required even at published dispensing limits

Prior authorization may be required: Brand‑only listings and high‑cost medications often require PA even when requested at the listed Dispensing Limit. Confirm PA requirements for each drug with the payer.

If PA is required for the listed product, do not assume coverage based solely on the Dispensing Limit — follow PA process before dispensing.

Prior Authorization

PA required for above‑limit dispensing or at risk for denial

Prior authorization for above‑limit dispensing: Requests that exceed the Dispensing Limit may be denied or require PA. Submit a complete PA with clinical rationale and supporting documentation to avoid claim denial.

Include prior treatment history, reason for increased quantity, and any relevant lab/clinical measures.
Without an approved PA, the member may be responsible for the excess cost.

Denial Risk

Denial risk and member cost responsibility when exceeding limits

Dispensing limit exceedance — denial or member cost risk: If a prescription exceeds the plan’s dispensing limit, the excess quantity may be non‑covered and the member will be responsible for full cost of the excess.

Pharmacies should verify plan limits before dispensing; direct members/providers to member services or plan materials for confirmation.
For disputed denials, provide clinical documentation and consider submitting an appeal or PA.

Billing Rule

Ensure pharmacy claims adhere to quantity limits

Quantity limit exceedance — operational guidance: Requests exceeding the stated limit (tablets, mLs, pens, syringes, kits) may be denied or require PA. Ensure the pharmacy claim quantity matches the dispensed quantity and the applicable time period.

Claims should reflect the product, strength, and quantity consistent with listed limits (e.g., sensors per 28/30 days, pens/syringes per 28 days).
Cumulative limits across strengths/formulations must be considered when adjudicating.

Documentation Required

Documentation required to support overrides and exceptions

Support for overrides: When requesting an override or exception to a dispensing limit, include thorough documentation (clinical rationale, dosing calculations, weight‑based dosing, prior treatment failure) to support the request.

For factor or C1 esterase inhibitor products, include IU/vial calculations and dosing justification.
Attach relevant clinical notes, monitoring data, and prior authorization denials/appeals if available.

Documentation Required

Provide supporting documentation for quantity exceptions

Quantity limit documentation: Dispensing limits are specified per drug and formulation; provide clear documentation when requesting coverage for quantities above the listed limit. Calculations and cumulative limits across strengths may be required.

Examples: vials/IU calculations for clotting factors, cumulative syringe limits for insulin supplies, and carton equivalencies for multi‑syringe packs.
Submit weight‑based calculations or specialty dosing worksheets when appropriate.

Billing Rule

Claims must reflect dispensing limits and packaging equivalencies

Dispensing limit documentation and claim adherence: Pharmacy claims must adhere to dispensing limits and the B/BG/G designation. Packaging equivalencies (e.g., 1 carton = 12 syringes) should be applied when documenting quantities.

Verify packaging and carton counts when submitting claims to ensure accurate quantity and compliance with QL rules.
If dispensing a different package configuration, include an explanation and supporting documentation.

Billing Rule

Adhere to required dispensing quantities on claims

Required dispensing quantity adherence: Pharmacies should dispense quantities consistent with the listed limits (for example, 30 tablets per 30 days, 2 inhalers per 30 days, 300 syringes per 30 days for insulin syringes) and confirm cumulative limits across strengths.

Failure to adhere to the listed Dispensing Limit may result in claim denial or member financial responsibility.
When in doubt, contact the payer or refer the prescriber to submit a PA with clinical justification.

Billing Rule

GLP‑1 class fill limit — operational note

GLP‑1 agent fill limit reminder: Reinforces that only one GLP‑1 agent and one strength may be filled in a 28‑day period. Pharmacies must enforce this rule and verify refills accordingly.

Refill windows and the one‑agent/one‑strength rule apply across all listed GLP‑1 products.
If a patient requires a change in agent or strength within the 28‑day window, a PA or clinical justification may be necessary.

Documentation Required

Documentation checklist for quantity exceptions and device replacements

Required quantity documentation: For coverage of requested quantities (especially above standard limits), include clinical notes, dosing schedules, prior attempts, and any lab or monitoring data that support the request.

For device/kit replacement (e.g., insulin pumps, CGM receivers), provide documentation supporting timing consistent with listed replacement intervals (e.g., 1 kit per 720 days, 1 receiver per 365 days).
Include manufacturer packaging and dosing details when relevant.

Step Therapy

Step therapy — check full formulary/policy

Step therapy not specified in excerpt: The provided dispensing limit list does not enumerate step therapy requirements. Providers should assume step therapy may apply for certain agents and consult the payer’s full formulary and PA rules for any step therapy protocols.

If step therapy is suspected, verify prior‑line therapy requirements and include prior medication history in any PA submission.
Contact member services or the PA portal to confirm step therapy applicability before dispensing.

Policy Background and Purpose

Dispensing limits are intended to encourage medication use consistent with FDA guidance and standard prescribing patterns by capping the quantity covered per prescription or over a specified time period. The policy summarizes its intent: coverage is limited to the specified dispensing quantities per drug/formulation, limits may vary by plan or state, and members may obtain quantities beyond the limit but will be responsible for the full cost of the excess.

Step-Therapy / Fill Limit Rules

Step	Requirement
1	Fill limit enforces one GLP-1 agent and one strength per 28 days
Notes: This fill/step restriction applies to listed GLP-1 injectables (e.g., dulaglutide) — only one agent and one strength may be dispensed within any 28-day period.

Step	Requirement
1	Fill limit of one injectable GLP-1 agent and one strength per 28 days
Notes: Applies to exenatide and other GLP-1 injectables listed — refill windows and dispensing limits specified per product; pharmacies must enforce one agent/strength per 28 days.

Policy Summary

PayerBlue Cross Blue Shield - Oklahoma

PolicyEnhanced Dispensing Limits (DL)

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateN/A

Key ActionVerify plan-specific dispensing limits or exclusions with the member's plan or by calling the number on the back of the member ID card.

SourceLink

On This Page

OpenPayer

Enhanced Dispensing Limits (DL)

Coverage Criteria and General Rules

Formulary Codes, Sample Thresholds, and Common Limits

Per-Product Quantity Limits (Selected Entries)

Actionable Notes for Providers and Pharmacies

Policy Background and Purpose

Definitions

Step-Therapy / Fill Limit Rules

Selected Detailed Quantity Limit Entries

Policy Revision History